Elizabeth Brem, MD
Hematology & Oncology · Orange, CANPI 1578883781
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $221,056 of the $335,320 with a category attached, or 65.9%. It is spread thinly across 28 manufacturers, the largest accounting for just 19.7%. 2025 is the largest year on record at $82,802, 2.3 times the $36,222 reported in 2019. Among hematology & oncology clinicians in CA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 307 payments — averaging $1092.25 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$66K
- E.r. Squibb & Sons, L.L.C.$59K
- Seagen Inc.$33K
- Beigene USA, Inc.$29K
- Pharmacyclics LLC, An Abbvie Company$25K
- ADC Therapeutics America, Inc.$25K
- plus $97K from 22 others
Across 92 payments — averaging $10,821 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Incyte Corporation$376K
- Regeneron$169K
- Gilead$123K
- Astrazeneca UK Limited$112K
- AbbVie$64K
- Janssen Research & Development, LLC$60K
- plus $92K from 3 others
What the payments were for
- Consulting fees$84,79525%
- Speaking & faculty fees$221,05666%
- Travel & lodging$21,8347%
- Food & beverage$7,3582%
- Education$2770%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 50 | $66,005 |
| E.r. Squibb & Sons, L.L.C. | 33 | $58,884 |
| Seagen Inc. | 27 | $33,294 |
| Beigene USA, Inc. | 25 | $29,015 |
| Pharmacyclics LLC, An Abbvie Company | 24 | $25,451 |
| ADC Therapeutics America, Inc. | 23 | $25,366 |
| Johnson & Johnson | 44 | $21,242 |
| Genentech USA, Inc. | 16 | $15,966 |
| Incyte Corporation | 10 | $12,146 |
| Genmab U.S., Inc. | 7 | $7,492 |
| AbbVie | 7 | $6,554 |
| Morphosys AG | 4 | $5,781 |
| Regeneron | 6 | $5,517 |
| Sanofi | 1 | $4,732 |
| Pfizer | 2 | $4,221 |
| Morphosys, US Inc. | 1 | $2,655 |
| Gilead | 3 | $2,449 |
| Sobi, Inc | 1 | $2,310 |
| Beone Medicines USA, Inc. | 6 | $2,125 |
| Bayer | 1 | $1,260 |
| Acrotech Biopharma Inc. | 5 | $1,022 |
| Karyopharm Therapeutics Inc. | 2 | $875 |
| Bristol Myers Squibb | 3 | $656 |
| Janssen Scientific Affairs, LLC | 1 | $125 |
| Epizyme, Inc. | 2 | $89 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $40 |
| Lilly USA, LLC | 1 | $25 |
| Secura Bio, Inc. | 1 | $21 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$335,320 in reported general payments places this provider in the 95th percentile of 1,363 hematology & oncology providers in California.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| ImbruvicaIbrutinib | 22 | $422,814 |
| Lenalidomide | 31 | $385,889 |
| RevlimidLenalidomide | 19 | $356,692 |
| PomalystPomalidomide | 13 | $287,521 |
| BrukinsaZanubrutinib | 16 | $227,606 |
| VenclextaVenetoclax | 23 | $121,159 |
| Gammagard LiquidImmun Glob G(Igg)/Gly/Iga Ov50 | 12 | $35,054 |
| XareltoRivaroxaban | 18 | $18,451 |
| Entecavir | 27 | $10,572 |
| Ondansetron Hcl | 12 | $1,649 |
| ValacyclovirValacyclovir Hcl | 12 | $701 |
| Acyclovir | 18 | $400 |
| Dexamethasone | 15 | $257 |
| Ondansetron OdtOndansetron | 27 | $216 |
| Gabapentin | 21 | $201 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Pharmacyclics LLC, An Abbvie CompanyImbruvica | $25,451 | $422,81422 claims |
| Bristol Myers SquibbRevlimid | $656 | $356,69219 claims |
| E.r. Squibb & Sons, L.L.C.Pomalyst | $58,884 | $287,52113 claims |
| Beigene USA, Inc.Brukinsa | $29,015 | $227,60616 claims |
| AbbVieVenclexta | $6,554 | $121,15923 claims |
| Takeda Pharmaceuticals U.S.A., Inc.Gammagard Liquid | $40 | $35,05412 claims |
| Johnson & JohnsonXarelto | $21,242 | $18,45118 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 1,363 hematology & oncology providers in California.
Other hematology & oncology in Orange
- Catherine CoombsOrange$786K
- Arash Rezazadeh KalebastyOrange$516K
- Misako NagasakaOrange$507K
- May ChoOrange$334K
- Angela FleischmanOrange$255K
- Dennis SlamonLos Angeles$3.1M
- Sandra HorningStanford$2.5M
- Mohammadbagher ZiariCorona$2.5M
- George YaghmourLos Angeles$1.9M
- Robert VescioWest Hollywood$1.1M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.